Key PointsSales of Eli Lilly's GLP-1 drugs are growing very quickly.Eli Lilly continues to innovate in the competitive GLP-1 space.The company is using the profits from GLP-1 drugs to invest in its business.10 stocks we like better than Eli Lilly › There are some good reasons why investors might want to avoid Eli Lilly (NYSE: LLY). For example, its price-to-earnings ratio is high at 40x, and its yield is very low at just 0.6%. But there are also…